Back to Search
Start Over
The treatment of inflammatory facial dermatoses with topical corticosteroids: focus on clocortolone pivalate 0.1% cream.
- Source :
-
Journal of drugs in dermatology : JDD [J Drugs Dermatol] 2012 Oct; Vol. 11 (10), pp. 1194-8. - Publication Year :
- 2012
-
Abstract
- Objective: Study results evaluating the efficacy and safety of clocortolone pivalate 0.1% cream in the treatment of adults, young children, and infants with inflammatory facial dermatoses are reported in this article. Clocortolone pivalate 0.1% cream, indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, is a mid-potency topical corticosteroid (Class 4) that has been studied and used extensively to treat a variety of corticosteroid-responsive inflammatory dermatoses, many of which often involve facial skin in both adults and children.<br />Methods: Clocortolone pivalate 0.01% cream was applied to affected facial skin in subjects presenting with seborrheic dermatitis, contact dermatitis, atopic dermatitis, or psoriasis. Application was completed three times daily for 21 days. Assessments of erythema, edema, transudation, lichenification, scaling, pruritus and/or pain were completed at baseline and Days 4, 7, 14, and 21. Overall therapeutic response was assessed at all follow-up visits. Forty-nine subjects were entered, ranging in age from 1 month to 88 years of age. Thirty-eight subjects completed the studies, with 11 subjects lost to follow-up after the first visit. Individuals between the ages of 13 and 19 years were pre-emptively excluded to avoid potential application of a corticosteroid to acne-affected or acne-prone skin.<br />Results: Treatment with clocortolone pivalate 0.1% cream resulted in decreases in erythema, edema, transudation, lichenification, scaling, and pruritus/pain in 76% of treated study subjects. The overall therapeutic response in approximately two-thirds of the subjects (68%) was rated as good to excellent. There were 7 adverse events noted over the course of the study that were judged to be related to treatment, all of which were cutaneous and localized to the site of application (acneiform eruptions, burning, and folliculitis).<br />Conclusion: Clocortolone pivalate 0.1% cream was effective in relieving the signs and symptoms of corticosteroid-responsive inflammatory dermatoses involving facial skin, including seborrheic dermatitis, contact dermatitis, atopic dermatitis, and psoriasis. Overall, the safety profile was favorable and devoid of any treatment-related serious adverse events.
- Subjects :
- Adult
Aged
Aged, 80 and over
Child
Child, Preschool
Dermatitis, Atopic complications
Dermatitis, Atopic drug therapy
Dermatitis, Contact complications
Dermatitis, Contact drug therapy
Dermatitis, Seborrheic complications
Dermatitis, Seborrheic drug therapy
Edema drug therapy
Edema etiology
Erythema drug therapy
Erythema etiology
Exudates and Transudates drug effects
Facial Dermatoses complications
Female
Fluocortolone adverse effects
Fluocortolone therapeutic use
Glucocorticoids adverse effects
Humans
Infant
Male
Middle Aged
Pain drug therapy
Pain etiology
Pruritus drug therapy
Pruritus etiology
Psoriasis complications
Psoriasis drug therapy
Skin Cream
Treatment Outcome
Young Adult
Facial Dermatoses drug therapy
Fluocortolone analogs & derivatives
Glucocorticoids therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1545-9616
- Volume :
- 11
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Journal of drugs in dermatology : JDD
- Publication Type :
- Academic Journal
- Accession number :
- 23134984